Matt Lorenz
Director, Bio Pivotal Analytical Development Gilead Sciences
Matt Lorenz is a Director in Bio Pivotal Analytical Development at Gilead Sciences, where he leads analytical development strategies supporting late stage and pivotal biologics programs. Matt brings deep expertise in the analytical development and characterization of monoclonal antibodies and ADCs, with a strong focus on applying advanced analytical approaches to enable robust, science driven decision making. He holds a PhD in Analytical Chemistry from the University of Michigan and has extensive experience advancing biologics from development through clinical and regulatory milestones at Gilead.
Seminars
As the ADC field shifts to novel payload mechanisms and more complex ADC design to deliver meaningful patient impact, quality characterization and control strategies need to be adapted and updated to keep up with the rate of ADC innovation.
Join this workshop led by big pharma leaders and members of the IQ consortium to investigate best approaches for non-cytotoxic and non-traditional ADC control strategies.
Workshop highlights include:
- Defining the control strategy for noncytotoxic bioconjugates including AOCs and antibody–peptide conjugates across CQAs, release testing, and stability
- Comparing control strategies for noncytotoxic versus cytotoxic bioconjugates, highlighting differences in potency assays, impurity profiles, and safety controls
- Applying patient centric quality control to non-cytotoxic bioconjugates by linking specifications to clinical relevance
